356 related articles for article (PubMed ID: 23519057)
1. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality.
Makubate B; Donnan PT; Dewar JA; Thompson AM; McCowan C
Br J Cancer; 2013 Apr; 108(7):1515-24. PubMed ID: 23519057
[TBL] [Abstract][Full Text] [Related]
2. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer.
McCowan C; Shearer J; Donnan PT; Dewar JA; Crilly M; Thompson AM; Fahey TP
Br J Cancer; 2008 Dec; 99(11):1763-8. PubMed ID: 18985046
[TBL] [Abstract][Full Text] [Related]
3. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study.
McCowan C; Wang S; Thompson AM; Makubate B; Petrie DJ
Br J Cancer; 2013 Sep; 109(5):1172-80. PubMed ID: 23949153
[TBL] [Abstract][Full Text] [Related]
4. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
Gierach GL; Curtis RE; Pfeiffer RM; Mullooly M; Ntowe EA; Hoover RN; Nyante SJ; Feigelson HS; Glass AG; Berrington de Gonzalez A
JAMA Oncol; 2017 Feb; 3(2):186-193. PubMed ID: 27711920
[TBL] [Abstract][Full Text] [Related]
5. Adherence to adjuvant endocrine therapy in women with breast cancer.
Danilak M; Chambers CR
J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
[TBL] [Abstract][Full Text] [Related]
6. Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution.
Hwang GS; Paranjpe R; Opsomer C; Lu K; Abajue U; Abughosh S; Zaghloul H; Trivedi MV
Clin Breast Cancer; 2020 Dec; 20(6):520-526. PubMed ID: 32669209
[TBL] [Abstract][Full Text] [Related]
7. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
8. Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
Wulaningsih W; Garmo H; Ahlgren J; Holmberg L; Folkvaljon Y; Wigertz A; Van Hemelrijck M; Lambe M
Breast Cancer Res Treat; 2018 Nov; 172(1):167-177. PubMed ID: 30030708
[TBL] [Abstract][Full Text] [Related]
9. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Chlebowski RT; Schottinger JE; Shi J; Chung J; Haque R
Cancer; 2015 Jul; 121(13):2147-55. PubMed ID: 25757699
[TBL] [Abstract][Full Text] [Related]
11. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.
Weaver KE; Camacho F; Hwang W; Anderson R; Kimmick G
Am J Clin Oncol; 2013 Apr; 36(2):181-7. PubMed ID: 22314001
[TBL] [Abstract][Full Text] [Related]
12. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer.
Aiello Bowles EJ; Boudreau DM; Chubak J; Yu O; Fujii M; Chestnut J; Buist DS
J Oncol Pract; 2012 Nov; 8(6):e149-57. PubMed ID: 23598850
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
Chung CT; Carlson RW
Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S18-23. PubMed ID: 15347435
[TBL] [Abstract][Full Text] [Related]
15. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
16. The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
Van Asten K; Poppe A; Punie K; Jongen L; Lintermans A; Wildiers H; Neven P
Curr Treat Options Oncol; 2015 Jul; 16(7):31. PubMed ID: 26031545
[TBL] [Abstract][Full Text] [Related]
17. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA
Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):812-820. PubMed ID: 30861596
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D
Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.
Haque R; Ahmed SA; Fisher A; Avila CC; Shi J; Guo A; Craig Cheetham T; Schottinger JE
Cancer Med; 2012 Dec; 1(3):318-27. PubMed ID: 23342281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
